Anacetrapib
Drug profile tracks the path of anacetrapib from Merck development into a 76-week international phase III trial (Am J Cardiovasc Drugs 2010)
Original title: Anacetrapib
Merck & Co. was developing anacetrapib (MK 0859), a selective CETP inhibitor, for atherosclerosis, hypercholesterolemia, and mixed dyslipidemia. This profile reports that add-on anacetrapib therapy was being evaluated in a 76-week phase III trial enrolling patients with coronary heart disease or CHD-risk-equivalent disease across the United States, Germany, Spain, and Austria, and discusses the development history and scientific profile of the compound at this stage of its clinical program.
Original abstract
Merck & Co. is developing anacetrapib (MK 0859; MK-0859; MK0859), a selective cholesterol ester transfer protein (CETP) inhibitor, as a treatment for atherosclerosis, hypercholesterolemia, and mixed dyslipidemia. Add-on therapy with anacetrapib is currently being evaluated in a 76-week phase III trial in patients with coronary heart disease (CHD) or CHD risk-equivalent disease in the US, Germany, Spain, and Austria. This review discusses the development history and scientific profile of this new compound.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.